Prototype blood test detects people who will develop severe Covid-19

Australian scientists have created a prototype blood test that detects if a patient’s immune system has the capacity to fight SARS-CoV-2, the virus that causes Covid-19.

The test detects high levels of two key chemical signals that are produced by T cells, the type of white blood cells that recognise and destroy infected cells.  

The two signals – interferon gamma and interleukin-2 – are both involved in killing virus-infected cells and encouraging other T cells to come to the infected area.  

Patients that have low levels of these two chemical signals may be more prone to the severe effects of Covid-19, including death. 

The Queensland-based study authors say the test could be important during the wait for vaccines to roll out worldwide.  

Australian researchers have developed a prototype blood test that can detect if a COVID-19 patient’s immune system has the capacity to fight the disease. They used the blood of Queenslanders who have recovered from the disease for their research. (stock image)

‘T cells produce a range of signalling molecules when they fight viruses,’ said Dr Corey Smith from QIMR Berghofer in Brisbane.

‘These signalling molecules are basically indicators of whether T cells are responding to the SARS-CoV-2 virus and are mobilising the immune army to launch an attack.

‘If we can find a way to detect whether or not they are present, then we can find out whether or not a patient’s immune system is responding as it should.’

There is evidence that SARS-CoV-2-specific T-cell responses are likely to provide long-term protection against the disease. 

T-cells (pictured) are a type of white blood cells that binds to and kills viruses. The prototype test detects high levels of two key chemical signals that are produced by T cells when they recognise SARS-CoV-2-infected cells

T-cells (pictured) are a type of white blood cells that binds to and kills viruses. The prototype test detects high levels of two key chemical signals that are produced by T cells when they recognise SARS-CoV-2-infected cells

Strategies to rapidly assess T-cell responses are therefore likely to be important for assessing immunity, the experts say. 


T cells are cells produced by the immune system to help the body destroy invading viruses and to remember how to do so if someone gets infected again. 

When the body is invaded by bacteria, a virus or parasites, an immune system alarm goes off, setting off a chain reaction of cellular activity in the immune system. 

T lymphocytes (T cells) are white blood cells that are a major part of the immune system.

They are part of the adaptive immune system, which is considered the more specialised response. They use past interactions to remember foreign threats and how to attack them. 

The adaptive immune system kicks in after the innate immune system, which is the immediate response to a virus, or ‘first line of defence’. 

There are several different types of T cells, including killer T cells directly kill the body’s own cells that have already been infected by a foreign invader, and helper T cells, which stimulate other parts of the immune response.  

For their study, researchers used the blood of 44 donors in Queensland, Australia, who had recovered from the disease – 17 men and 27 women aged between 20 and 75. 

The goal was to find out which combination of viral peptides – the virus’s short chains of amino acids – could be used to stimulate T cells in the lab.

‘We screened a range of SARS-CoV-2 peptides to work out which combination could be used to detect a successful T cell immune response,’ said Professor Smith.

‘We isolated the T cells from the donated blood, exposed them to viral peptides and measured the production of a number of different signalling molecules. 

‘We then compared the levels produced by T cells from the recovered Covid-19 patients with levels released by T cells from 20 healthy donors who had never been infected with SARS-CoV-2.’ 

T cells from those who had recovered from Covid-19 produced larger amounts of the two signalling molecules, the team found. 

Interferon gamma (IFNγ) and interleukin-2 (IL-2), and to a lesser extent the pro-inflammatory cytockine IL-8, were the top candidates for differentiating between SARS-CoV-2-specific responses of recovering Covid-19 patients and individuals unexposed to the virus. 

The team hope the discovery could be used to identify early on which patients’ immune systems are not responding appropriately, and who might therefore be at higher risk of becoming seriously unwell. 

The research took place in Australia, which has been largely successful in controlling Covid-19 infection rates.

But a blood test for early immune response to the virus could particularly help other countries experiencing second and third waves.

‘Now that we’ve refined a way to detect whether or not T cells are reacting to SARS-CoV-2, we believe this information could be used to develop a blood test,’ said QIMR Berghofer researcher Dr Katie Lineburg.

‘A blood test could help doctors identify patients whose T cells have not started mounting an immune response and who are therefore not fighting the virus and are at higher risk of becoming seriously unwell. 

‘Those patients could then be monitored more closely to ensure they receive treatment early, rather than waiting until they experience severe symptoms.’

In the UK, the Pfizer/BioNTech coronavirus vaccination, which is 95 per cent effective at blocking infection, will be administered at 50 hospital hubs from Tuesday.

But according to Dr Lineburg, a blood test that could detect whether a patient is developing an effective immune response would be an important tool during the wait for vaccines. 

In Australia, the University of Queensland is developing a vaccine in partnership with pharmaceutical company CSL – and the federal government has ordered 51 million doses.

But Australia’s domestically-made coronavirus vaccine will not be ready until mid-2021, according to Aussie scientists

Four vaccines developed overseas, including the Pfizer vaccine, will roll out from March in Australia if they are approved. 

A graphic demonstrates the order of priority in which the vaccine will be rolled out in the UK, starting with residents in care homes

A graphic demonstrates the order of priority in which the vaccine will be rolled out in the UK, starting with residents in care homes

‘While the world waits for a vaccine to be rolled out, it’s clear the virus will continue to spread and people will continue to get sick, placing more pressure on health systems,’ Dr Lineburg said.  

‘These are the first results from this Covid-19 study, and we will follow up with as many participants as possible in future, to improve our understanding of long-term immunity to the virus.’ 

More than 67 million cases of Covid-19 have been reported worldwide and the disease has caused more than 1.53 million deaths, according to Johns Hopkins University data. 

The study has been published in Clinical and Translational Immunology


Health bosses have told people over 80 not to panic if they have not been contacted about the coronavirus vaccine – as it is revealed that most of them will not get a jab until the New Year as mass immunisation begins.  

Vaccinations will be administered at dozens of hospital hubs from Tuesday, December 8 – on what has been dubbed ‘V-Day’ by Matt Hancock – with people aged 80 and over, care home staff and NHS workers at higher risk at the front of the queue.  

Chris Hopson, chief executive of NHS Providers, said people need to ‘hang fire’ and be assured that they have not been forgotten about, despite not receiving a letter or a phone call about the vaccine.

He told the PA news agency: ‘I don’t think people should expect anything over the next few days because the reality is, as I said, that for the vast, vast, vast majority of people this will be done in January, February, March.

‘And the one thing that we don’t want people to get anxious about or concerned about is ‘Where’s my letter?’ in December.’ He added: ‘People really shouldn’t worry if they’re over 80 and they haven’t had a letter.

‘I’m sure there will be communications over the next few weeks that will tell people how quickly we are getting through the over-80s, and there will be plenty of communications to say, at the right point, if you haven’t had a letter then you should talk to your GP, but we are many weeks away from that.

‘So as I said people just need to hang fire and wait for a proactive communication.

‘If that hasn’t happened, don’t worry, we haven’t forgotten you, and we’ll certainly tell you at the point at which you need to start worrying if you haven’t been contacted, but that will be many, many weeks away.’

The UK has ordered 40 million doses of the Pfizer/BioNTech jab, enough to vaccinate 20 million people, as people need to receive two doses. There are 800,000 doses in the first tranche, meaning that 400,000 people will be vaccinated initially.

Source link

Related Articles

Back to top button